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Background: The key role of egfr in thymoma pathogenesis has been questioned following the failure in 
identifying recurrent genetic alterations of egfr coding sequences and relevant egfr amplification rate. We 
investigated the role of the non-coding egfr CA simple sequence repeat 1 (CA-SSR-1) in a thymoma case 
series.
Methods: We used sequencing and egfr-fluorescence in situ hybridization (FISH) to genotype 43 
thymomas; (I) for polymorphisms and somatic loss of heterozygosity of the non-coding egfr CA-SSR-1 
microsatellite and (II) for egfr gene copy number changes.
Results: We found two prevalent CA-SSR-1 genotypes: a homozygous 16 CA repeat and a heterozygous 
genotype, bearing alleles with 16 and 20 CA repeats. The average combined allele length was correlated with 
tumor subtype: shorter sequences were significantly associated with the more aggressive WHO thymoma 
subtype group including B2/B3, B3 and B3/C histotypes. Four out of 29 informative cases analysed for 
somatic CA-SSR-1 loss of heterozygosity showed allelic imbalance (AI), 3/4 with loss of the longer allele. 
By egfr-FISH analysis, 9 out of 33 cases were FISH positive. Moreover, the two integrated techniques 
demonstrated that 3 out of 4 CA-SSR-1-AI positive cases with short allele relative prevalence showed 
significantly low or high chromosome 7 “polysomy”/increased gene copy number by egfr-FISH.
Conclusions: Our molecular and genetic and follow up data indicated that CA-SSR-1-allelic imbalance 
with short allele relative prevalence significantly correlated with EGFR 3+ immunohistochemical score, 
increased egfr Gene Copy Number, advanced stage and with relapsing/metastatic behaviour in thymomas. 
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of heterozygosity; egfr-fluorescent in situ hybridization (egfr-FISH)
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Introduction 
Among thymic epithelial tumors (TET), thymomas are 
heterogeneous in biology and clinical behaviour, whereas 
carcinomas (C) are clearly aggressive from the beginning (1). 
EGFR overexpression has been linked with advanced 
stage (2). However, in a recent report, progression free 
survival (PFS) and overall survival (OS) appeared to be 
improved in EGFR positive thymomas (3). It is important 
to note that egfr mutations are exceedingly rare in 
thymomas (4) and egfr amplification rate is low (30%) 
and associated with EGFR protein overexpression by 
immunohistochemistry (5). Recent data reported increased 
egfr Gene Copy Number (GCN) as revealed by FISH 
in rare thymic carcinomas but not in thymomas (6). 
Moreover, in a bright-field in situ hybridization (BISH) 
study, egfr GCN was found to be increased in 39/138 
TET oriental cases and cases with egfr gains showed 
better outcome than cases with egfr native status (7). 
Relevance of egfr gene has also been suggested by the 
efficacy of EGFR-targeted therapies in sporadic cases of 
pretreated relapsing thymomas (8,9). However, molecular 
mechanisms underlying EGFR overexpression have been 
largely enigmatic and epigenetic mechanisms could play a 
role. Our aim was to investigate whether a key regulatory 
mechanism that controls egfr transcription and expression 
in breast carcinomas (10,11)—namely a polymorphism and 
loss of heterozygosity (LOH) of the functional CA-SSR-1 
microsatellite—may also be involved and characterized in 
a clinically annotated thymoma cohort. The CA simple 
sequence repeat 1 (CA-SSR-1) microsatellite lies inside egfr 
intron 1 and occurrence of shorter variants is associated 
with higher pre-m-RNA transcription levels in several 
tumour systems (10,12). Therefore, we performed CA-
SSR-1 length and LOH analyses and correlated the results 
with EGFR-immunohistochemistry (EGFR-IHC), with 
egfr-fluorescent in situ hybridization (egfr-FISH) and with 
the clinicopathological and follow up (FU) data. 
Materials and methods
Patient series 
A total of 43 thymoma cases surgically treated between 
1990 and 2009 at the Thoracic Surgeries of Regina Elena 
National Cancer Institute and of Catholic University of 
Rome were included in the study. The main demographical 
and clinicopathological features are shown in Table 1. The 
availability of formalin-fixed paraffin-embedded (FFPE) 
tumor tissue as well as of normal peritumoral thymic tissue 
or other normal matched tissue were major criteria in case 
selection. Primary tumors were considered; in three cases 
(no. 26, 41 and 43, Table 2) only tissue from the relapsed 
neoplasia was available. Diagnoses were reviewed according 
to the WHO classification (1) by two independent 
pathologists (MM, LL). Masaoka’s system was applied as 
staging system (14). This retrospective study was reviewed 
and approved by the Institutional Ethics Committee of 
our Institute. The need for individual patient consent was 
waived because individuals were not identified in the study.
EGFR immunohistochemistry (EGFR-IHC) 
EGFR immunostains were performed on FFPE Tumor 
slides with the Dako Cytomation PharmDx EGFR kit 
and evaluated by two independent pathologists (SS, 
MM) according to recommended scores, as reported in 
Supplementary material. 
Table 1 Main demographical and clinicopathological features 
of the cases included in the study
Patient characteristics No. %
Total patient No. 43 100
Male 19 44
Female 24 56
Age of diagnosis (yr)
Median 50
Age range 37-76
Thymoma histotype (WHO 2004) 
A 1 2.3
AB 6 13.9
B1 5 11.6
B1/B2 1 2.3
B2 15 35
B2/B3 7 16,3
B3 4 9.3
B3/C 4 9.3
Masaoka’s staging 
Stage I 10 23.2
Stage II 20 46.4
Stage III 13 30.4
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Table 2 Comparison of clinicopathological and molecular and genetic data
Case No. WHO Stage AD FU 
EGFR 
IHC
CA-SSR-1 
genotype
(CA)n 
sum
CA-SSR-1 
LOH
egfr-FISH
1 AB I MG N/A 1+ 16/17 33L (−) NA
2 AB I NO 7 yr, NED 2+ 20/20 40H NI NA
3 AB I NO 7 yr, NED 2+ 20/21 41H (−) NA
4 B1 I ND N/A 2+ 16/18 34L (−) ND
5 B1/B2 I NO 10 yr, relapse 2+ 16/16 32L NI ND
6 B2 I MG 5 yr, NED 1+ 16/19 35L (−) NA
7 B2 I NO N/A 2+ 15/19 34L (−) NA
8 B2 I MG 5 yr, NED 3+ 18/20 38H (−) ND
9 B2/B3 I MG N/A 2+ 16/16 32L NI NA
10 A II NO 6 yr, ET metastasis 2+ 16/20 36L (−) Trisomy
11 AB II MG N/A 2+ 16/18 34L (−) Trisomy
12 AB II NO N/A 2+ 16/16 32L NI NA
13 B1 II MG N/A 2+ 18/18 36L NI NA
14 B1 II NO 3 yr, NED 2+ 20/20 40H NI NA
15 B1 II NO N/A 1+ 16/20 36L (−) Trisomy
16 B1 II MG N/A 1+ 16/20 36L (−) NA
17 B2 II Other 4 yr; death for AD 1+ 18/18 36L NI NA
18 B2 II MG Postoperative death 2+ 16/16 32L NI ND
19 B2 II MG 9 yr, ET metastases 2+ 16/18 34L (−) NA
20 B2 II NO N/A 2+ 20/20 40H NI ND
21 B2 II NO 8 yr, NED 3+ 16/17 33L (−) ND
22 B2 II MG 4 yr, NED 3+ 16/21 37L (−) NA
23 B2 II ND N/A 3+ 17/20 37L (−) NA
24 B2 II MG N/A 3+ 18/20 38H (−) NA
25 B2/B3 II MG 3 yr, NED 2+ 16/17 33L (−) NA
26 B2/B3 II MG 6 yr, relapse 3+ 16/17 33L (−) NA
27 B3 II MG 11 yr; NED 2+ 15/21 36L (−) Trisomy
28 B3/C II ND Early death of disease 3+ 13/14 27L (−) ND
29 B3/C II NO 13 yr; relapses, ET metastasis, 
death
3+ 16/21 37L (−) ND
30 B3/C II MG 18 yr, relapses, death for C HT 
complications
3+ 16/16 32L NI NA
31 AB III NO 3 yr, NED 3+ 16/20 36L (−) < Low polysomy
32 B2 III MG 7 yr, NED 2+ 14/18 32L (−) NA
33 B2 III ND 2 yr, NED 3+ 16/19 35L (+) < Low polysomy
34 B2 III MG N/A 2+ 16/22 38H (−) NA
35 B2 III MG 4 yr, NED 2+ 20/22 42H (−) NA
36 B2/B3 III MG 15 yr; relapses; death of disease 3+ 16/- 16L NI Monosomy
37 B2/B3 III NO 4yr; relapses, death of disease 3+ 16/17 33L (−) NA
38 B2/B3 III NO N/A 3+ 20/20 40H NI ND
Table 2 (continued)
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Genomic DNA extraction, PCR amplification and 
mutation analysis of EGFR exon 21 by directed sequencing; 
EGFR CA-SSR-1 length microsatellite analysis
Manually microdissected epithelial cell-rich areas from 
representative FFPE tumor tissue slides as well as 
peritumoral thymic tissue or other normal tissue were 
selected for genomic DNA extraction and the molecular 
and genetic investigations. Peritumoral thymic tissues were 
selected in cases with a well-represented epithelial cell 
compartment or from involuted thymus with predominance 
of epithelial cells, as previously reported (15). Other normal 
FFPE tissue included matched mediastinal lymph nodes or 
lung parenchyma. After proteinase K digestion, genomic 
DNA was isolated with the QIAamp DNA FFPE Tissue 
Kit (Qiagen) and was used for PCR reaction to amplify 
egfr exon 21 and the egfr CA-SSR-1 microsatellite by 
specifically designed primers (Table S1). The PCR reactions 
were performed by using AmpliTaq Gold; sequencing 
reactions were analysed on a 3130 Genetic Analyzer (Applied 
Biosystems, Life technologies, Thermo Fisher) for egfr 
mutation and egfr CA-SSR-1 microsatellite length analyses. 
Methods were detailed in Supplementary material.
egfr CA-SSR-1 loss of heterozygosity (LOH)
egfr CA-SSR-1 LOH analysis was performed in 29/30 
informative cases by comparing tumor and matched 
peritumoral thymus/other normal tissues. Case no. 43 was 
not analysed for LOH as no normal tissue was available. 
Genomic DNA was analysed for CA-SSR-1-LOH by 
specifically designed primers (Table S1) (16). PCR reactions 
were done as reported in section 2.3; fragment separation 
was performed as shown in Supplementary material. The 
scans for constitutional heterozygous patients were analysed 
by comparison of the peak area of the two alleles in normal 
and tumour tissue by the following equation (17): LOH 
score = T1 X N2/T2 X N1, where T is tumour, N is normal, 
1 is the area under the peak corresponding to the shorter 
allele, and 2 is the area under the peak corresponding to 
the longer allele. The result was considered statistically 
significant different from the ratio of the normal allele 
peak areas when the LOH score was <0.79 (loss of the 
longer allele) or >1.27 (loss of the shorter allele) (16). The 
reliability of peak area and lengths for allelic imbalance 
(AI) score determination was tested by two runs for each 
independent PCR.
egfr-fluorescent in situ hybridization (egfr-FISH analysis)
egfr-FISH analysis was performed in 33 cases by using 
the EGFR/CEN-7 Probe Mix (Dako) as reported in 
Supplementary material. H&E-pre-selected histological 
areas were identified and evaluated by FISH. In ten cases 
FISH analysis could not be performed (among them case 
no. 40, an AI positive case with increase of the long allele) 
due to unavailability of left over material or for technical 
reasons. The egfr-FISH evaluation was performed by three 
independent observers (ADB, EG, MM) in a cell-by-cell 
approach, by counting at least in 100 non-overlapping 
interphase nuclei red and green signals respectively for 
Table 2 (continued)
Case No. WHO Stage AD FU 
EGFR 
IHC
CA-SSR-1 
genotype
(CA)n 
sum
CA-SSR-1 
LOH
egfr-FISH
39 B2/B3 III ND N/A 2+ 20/20 40H NI NA
40 B3 III MG 13 yr; relapse; alive 3+ 16/18 34L (+) > ND
41 B3 III MG 20 yr; relapse; death for 
complications
3+ 16/20 36L (+) < High polysomy
42 B3 III NO 6 yr; relapses; IT metastasis; lost 
to FU
3+ 16/20 36L (−) Trisomy
43 B3/C III MG 20 yr; relapse; death for 
complications
3+ 16/21 37L ND Low polysomy
N/A, not available follow up (<2 years); NI, not informative (homozygous); NA, not amplified; ND, not determined; (+) <, LOH of 
the longer allele; (+) >, LOH of the shorter allele; (CA)n sum, sum of CA of 2 alleles: low ≤37; H=, high ≥38 (13); NED, no evidence 
of disease; AD, autoimmune disease; FU, follow up; MG, Myasthenia gravis; NO, no autoimmune disease; IT, intrathoracic; ET, 
extrathoracic; CHT, chemiotherapy.
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egfr gene and chromosome 7 centromere. Samples were 
grouped as follows: normal disomy: ≤2 gene copies in >90% 
of cells; “trisomy”: 3 gene copies in >10% of cells and ratio 
gene/chromosomes ≤2; “low polysomy”: ≥4 gene copies in 
>10% but <40% of cells and ratio gene/chromosomes ≤2; 
“high polysomy”: ≥4 gene copies in >40% cells and ratio 
gene/chromosomes ≤2; gene amplification: ratio gene/
chromosome >2 or 15 gene copies in ≥10% of cells (18,19). 
Trisomy, low polysomy, high polysomy, and/or gene 
amplification were considered egfr-FISH positive (19).
Statistical analyses
Associations among genetic variables and clinicopathological 
characteristics were assessed by Spearman χ2 test or Fisher 
test, as appropriate. Differences in mean values were 
evaluated by the Student t-test. The overall threshold of 
significance was 0.05. The SPSS (version 18.0) statistical 
program (SPSS Inc., Chicago, IL, USA) was used for 
analyses.
Results
Clinical data 
In our study 43 Caucasian Thymoma patients were included 
(Table 1); Table 2 shows in detail the clinicopathological 
features, the FU data and the molecular and genetic variables 
investigated. In Stage I (9 cases) all thymoma subtypes 
were represented but the A subtype; in stage II (21 cases) 
there were: one A, two AB subtype cases and most cases were 
B subtype. Among these last there were three B3 thymomas 
with isolated squamous cell carcinoma foci (B3/C). 
In stage III with one notable exception (an AB case) all 
cases were B2 and B3 subtypes or “combined” B2/B3; one 
case was a B3/C case. Among the 38 cases with available 
informations, 22 patients had myasthenia gravis (MG), one 
patient had a severe form of Good’s syndrome and 15 patients 
were free of autoimmunity. FU data, available in 28 patients 
(65.12%), including two early death, one for surgical 
complications and one for disease, ranged 2 to 20 years, 
median 7 years. FU < to 2 years was not considered.
EGFR-immunohistochemistry (EGFR-IHC)
All cases were positive by EGFR-IHC (Table 2). All AB and 
B1 thymoma cases showed score 1+ or 2+, with a single 
exception of 3+ (AB case, no. 31, in stage III). All B2 cases 
except two and all B2/B3 and B3 cases showed a score 2+ 
or 3+, irrespective of clinical stage (I to III). B3/C cases 
received score 3+. The single A case (No. 10) had a 2+ 
score and was in Stage II. A significant statistical correlation 
by χ2 test was found between EGFR expression score and 
histological subtype (P=0.009) but only a trend with clinical 
stage (P=0.07).
EGFR mutation status and EGFR-CA-SSR-1 
microsatellite analyses
By tumor genotyping, no exon 21 egfr activating mutations 
were found. CA-SSR-1 allele length distribution and 
frequencies were shown in Figure 1. Alleles 13 to 17 
dinucleotide long repeat constituted about 50%, the 16 
long repeat being the most frequently represented. One 
case (“monosomic”) had only one CA-SSR-1 allele, 16 CA 
repeat long. Therefore the distribution of 85 alleles was 
Figure 1 Distribution of CA-SSR-1 allele length among Thymoma 
patients. The most frequent allele in our caucasian patient group 
was (CA)n =16 long (38%), followed by (CA)n =20 (24.7%), (CA)n 
=17 (7%), (CA)n =18 (13%), (CA)n =21 (5.8%), (CA)n =19 (3.5%), 
(CA)n =14 (2.3%), (CA)n =15 (2.3%), (CA)n =22 (2.3%), (CA)n 
=13 (1.1%). A total of 85 alleles were reported, as in case no. 36 
one allele was absent. This finding was confirmed by egfr-FISH 
analysis, as the tumor was chromosome 7” monosomic” (case no. 
36, Figure S1).
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shown in Figure 1. Thirty out of 43 cases were heterozygous 
(informative rate 70%) for CA-SSR-1 allele length. The 
prevalent genotype was heterozygous 16/20 CA (6 cases) 
followed by a homozygous genotype 16 CA (5 cases) and a 
heterozygous 16/17 CA repeats (5 cases). The allele length 
sum for (CA)n ((Ca)n Sum) (Sum of CA repeats of two 
alleles, or “combined” allele length) was calculated in each 
single case (Table 2) as well as by histotype (Table 3). Mean 
length values in the AB, B1, B2 group was 36.1, while in the 
B2/B3, B3 and B3/C group was 33.5, the differences in these 
two groups showed statistical significance by the Student t-test 
(P=0.05). In our series 33 cases, including the “monosomic” 
case, had an allele length sum ≤37 (Low repeats, “L”), and 
10 cases had an allele length ≥38 (High repeats, “H”) (113). 
egfr CA-SSR-1-LOH analysis 
By LOH analysis of 29/30 informative cases, 4/29 (13.8%), 
all in Stage III, showed AI at the CA-SSR-1 locus, 3/4 cases 
with loss of the long allele compared to the short allele 
(Table 2 and Figure 2A). Three out of 4 cases CA-SSR-1-AI 
positive were B (one B2 and two B3) and one case was an 
AB subtype. LOH data were comparable when thymus or 
a different tissue (a lymph node or lung parenchyma) was 
used as “normal” tissue source.
egfr-fluorescent in situ hybridization (egfr-FISH) analysis
Twenty two out of 33 cases were disomic; nine cases were 
egfr-FISH positive showing increased GCN and case no. 
36 was chromosome 7 “monosomic” (reported as having 
only one CA-SSR-1 microsatellite in the previous section 
on egfr mutation status and egfr-CA-SSR-1 microsatellite 
analyses; Table 2; Figure S1). Among FISH positive cases, 
5 cases were “trisomic”, 3 cases showed “low-polysomy” and 
one case showed “high polysomy” according to reported 
criteria (18,19) (Table 2 and Figure 2B). A disomic status was 
found in 100% of cases tested in stage I, in 75% of cases 
tested in stage II and in 45% of cases tested in stage III. 
“Trisomy” was observed in 25% of cases tested in stage II 
(4/16). In stage III, FISH positivity was found in 5/11 cases 
(45%) tested, trisomy being found in 9% (1/11 cases tested); 
both low (27%, 3/11) and high (9%, 1/11) polysomy were 
observed only in stage III. The single monosomic case was 
also in stage III.
Integrated correlation of molecular genetic/
immunohistochemical data and clinicopathological features 
The egfr-FISH analysis showed that three AI positive 
cases with relative increase of the shorter CA-SSR-1 
allele were FISH positive with low or high “chromosome 
7 polysomy”/increased GCN, thus suggesting that the 
increased gene copies carried the CA-SSR-1 shorter allele 
(cases no. 31, 33 and 41; Table 2, Figure 2A and B). Other 
five FISH positive cases (“trisomic” for chromosome 7) 
showed no detectable AI. Statistical analysis revealed a 
nearly significant correlation between sum length and FISH 
positivity, short allele sum (“L” status) being associated to 
positivity (9/9) (P=0.06). Moreover, among the 23 cases 
analyzed both by LOH and FISH, a statistically significant 
correlation among associated FISH and AI positivity 
(observed in three cases) was found with respect to AI 
negative cases (P=0.01). Further findings derived by 
correlating the egfr status with FU data, available in 28 
patients: no neoplastic adverse events were recorded 
among the five cases with CA-SSR-1 “H” status, with FU 
3 to 7 years. Among the CA-SSR-1 cases with “L” status 
(21 cases) (Figure 3), eight, including three FISH positive 
cases, did well (median FU 4 ys). Adverse events (relapses 
or metastases) were recorded in 12/21 CA-SSR-1 “L” 
cases (57.14%). Among these “L” cases, six had a range 
of egfr alterations (FISH positivity, AI, or chromosome 7 
“monosomy”). Among FISH positive cases, it is worthy to 
note that two patients, one with “low” and the other with 
“high” egfr polysomy, had multiple relapses, were long 
survivors and died after 20 years because of complications. 
Our “monosomic” case experienced long survival (15 years) 
with multiple relapses and ultimately death because 
of complications. Among the other six relapsing or 
Table 3 Comparison between thymoma histotypes and their 
frequency with the average “combined” allele length sum for 
(CA)n for each subtype
Thymoma 
histotype
No. of  
cases
(%)
(CA)n allelic  
sum average
A 1 2.3 36
AB 6 13.9 36
B1 5 11.6 36.4
B1/B2 1 2.3 32
B2 15 35 36.2
B2/B3 7 16.3 32.4
B3 4 9.3 35.5
B3/C 4 9.3 33.2
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Figure 3 Integrated correlation of molecular and genetic data and clinicopathological features in 21 cases with low-number (“L”) CA-
SSR-1 CA repeats (FU ≥2 yr). All WHO histotypes were represented with B2 to B3 cases representing the majority. Cases “L” which did 
well: no. 6, 21, 22, 25, 32; cases which did well but had egfr gene alterations: no. 27, 31, 33. Cases “L” which had relapse or metastases and 
had egfr alterations: no. 10, 40, 41, 42, 43; case no. 36 was “monosomic”. Cases “L” which had relapse or metastases, no detectable egfr gene 
alterations but had short CA-SSR-1 microsatellite: no. 5, 19, 26, 30, 37. Case “L” which had relapse or metastases, with no detectable egfr 
alterations and CA-SSR-1 microsatellite 37 repeat long: no. 29. The case “L”, FISH-/Not Informative for LOH with Good’s syndrome 
which had combined CA-SSR-1 microsatellite length of 36 was no. 17. *In this LOH+ case “(+) >”, with LOH of the shorter allele, the 
FISH status could not be determined (case No. 40, Table 2); ^NI for LOH = not Informative for LOH study (cases No. 17 and 36); Cases 18 
and 28 (early deaths) were not reported here. LOH, loss of heterozygosity; FISH, fluorescent in situ hybridization.
Figure 2 Relationship between CA-SSR-1-allelic imbalance (AI) and egfr-Gene Copy Number (GCN) increase/chromosome 7 “polysomy”. 
(A) Fragment analysis of the CA-SSR-1 locus of normal thymus (top) in comparison with thymoma (bottom). In the tumor tissue it is 
remarkable the loss of the longer with respect to shorter allele (allelic imbalance, AI); (B) the panel shows the egfr-FISH positive status (high 
polysomy; ≥4 gene copies in >40% cells) in the same case (case No. 41) (18,19).
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metastatizing patients with “L” CA-SSR-1, 5/6 cases had 
very short combined CA-SSR-1 allele length (32 to 34). 
Moreover, the patient with the shortest combined allele 
length (case No. 28, 27 Ca repeat sum) died shortly after 
surgery due to the disease. Case no. 26, included in the 
study as an example of early relapse, had also a very short [33] 
Ca repeat sum. 
Discussion 
Thymomas are slow-growing tumors, requiring long 
term FU; the average time to relapse was reported to 
be 8.5 years in a recent case series (20). We investigated 
the egfr polymorphic dinucleotide repeat microsatellite 
locus CA-SSR-1 length and AI and the egfr-FISH status 
in a clinically annotated Caucasian Thymoma series with 
on average long FU. By tumor genotyping, our thymoma 
series was found to bear similar CA dinucleotide repeat 
length (13 to 22 CA) frequency than reported in Caucasian 
populations (21). By considering the combined medium 
allele length, we showed that the shorter sequences were 
significantly mostly associated with the B2/B3, B3 and B3/C 
histotypes. The shorter egfr  CA-SSR-1 alleles and 
combined shorter CA-SSR-1 sequences have been related 
to increased egfr gene expression/mRNA synthesis (22). 
In other tumor systems, Caucasian patients with Head 
& Neck Squamous Cell Carcinomas (HNSCC) bearing 
short (<17) repeat number of egfr CA-SSR-1 were found 
to have poorer prognosis in comparison to patients with 
CA-SSR-1 repeat number ≥17 in both alleles (23). 
Increased risk was found in esophageal cancer patients 
with CA-SSR-1 short alleles (cut off ≤18) (24). No 
mutations were found in our series in exon 21, as already 
reported (4); mutations were neither found in CA-SSR-1 
AI positive cases, at variance with lung cancer (22). The 
finding of egfr-CA-SSR-1 microsatellite AI in 4/29 cases 
represents an aberrant genomic somatic signature 
previously unreported in thymoma. The occurrence of AI 
with respect to peritumoral thymic tissue suggested that 
there was no “zone” phenomenon as reported in breast 
cancer (25). Among our FISH positive cases only those 
cases with “polysomy”, both low or high, were associated 
to CA-SSR-1-AI, probably because the slight increase in 
GCN occurring in “trisomic” cases was not sufficient to be 
detected as LOH. Moreover, we cannot exclude that the 
long history and previous treatments had induced secondary 
egfr genetic changes in one (case no. 41) of the four cases 
bearing AI. Recently, increased FISH-determined egfr 
GCN gain was found to have prognostic significance in 
Head and Neck Squamous Cell Carcinomas (HNSCC) (26). 
In thymomas a predictive value of egfr GCN gain, could 
also be argued, as the case AI positive no. 41 in our series 
was treated in second line with Cetuximab with partial 
response (8). In other tumor systems, the integrated 
assessment of egfr polymorphisms, histopathological 
features and staging factors were shown to contribute to 
prognostic estimates in breast cancer (27). Our pilot study 
data indicated that egfr short CA-SSR-1 sequences were 
significantly associated with the more aggressive B2/B3, B3 
and B3/C WHO histotype groups (28) Furthermore, egfr-
FISH positivity was associated with malignant behaviour 
in thymomas in 5 out of the 7 cases with available FU. 
Moreover, the occurrence of adverse events in patients with 
the previous mentioned egfr “alterations” appears to be of 
note both in limited stages (I-II) and in advanced stage (III). 
Finally, by integrating LOH and egfr-FISH data we showed 
here that the increased egfr GCN carried on the shorter 
microsatellite allele in 3 out of 4 cases, a finding previously 
not described in thymoma. 
Conclusions 
Our pilot study showed that an egfr-related “signature”, 
mostly but not exclusively B-histotype related, with short 
CA-SSR-1, AI for the intron 1 microsatellite CA-SSR-1 and 
increased egfr GCN could be relevant both for progression 
and therapeutical purposes in thymoma. The role of egfr-
CA-SSR-1 microsatellite and of similar (TG/CA)n repeats 
occurring in intron 1 of other cancer-related genes has been 
recently questioned as a class of universal gene expression 
regulators (29). Therefore a larger prospectively collected 
thymoma series should be investigated to acquire further 
insight in thymoma-specific egfr transcription regulatory 
mechanisms.
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Supplementary
Supplementary material
EGFR immunohistochemistry (EGFR-IHC)
EGFR immunohistochemistry was performed with the 
Dako Cytomation PharmDx EGFR kit. Briefly, only tumor 
cell membrane EGFR expression was defined positive and 
was graded 0 to 3. An intensity score was applied as follows: 
negative = no reaction; 1+ if the neoplastic cells displayed 
an incomplete, weak plasmamembrane/cytoplasmic 
immunostaining; 2+ if neoplastic cells displayed a complete 
plasmamembrane immunostaining with moderate 
intensity; and 3+ if neoplastic cells displayed a complete 
plasmamembrane strong immunostaining. Score 2+ and 3+ 
were considered overexpression.
egfr exon 21 PCR Amplification and mutation analysis by 
direct sequencing 
PCR reactions were in a volume of 50 µL which contained; 
10 pmol of each primer, 0.25 mM each dNTP, 2.5 mM 
MgCl2, 3 units of AmpliTaq Gold (Applied Biosystems (AB), 
Life Technologies, Thermofisher), 1X Taq Gold buffer 
(AB, Life Technologies, Thermofisher), and the appropriate 
volume of H2O. A thermocycle touchdown PCR protocol 
was as follow: 10 minutes at 95 ℃, 8 cycles at 95 ℃ for 30 
seconds, 59 ℃ for 30 seconds, and 72 ℃ for 30 seconds, 
followed by 30 cycles at 95 ℃ for 30 seconds, 57 ℃ for 
30 seconds, and at 72 ℃ for 30 seconds followed by 72 ℃ 
for 10 minutes. PCR products were sequenced directly by 
using the Big Dye V3.1 Cycle-Sequencing kit (AB, Life 
Technologies, Thermofisher) with proper reverse primers 
(Table S1). After sequencing reaction, 1 µL of every mixture 
was purified by BigDye XTerminator Purification Kit (AB, 
Life Technologies, Thermofisher) and analyzed on 3130 
Genetic Analyzer (Applied Biosystems, Life Technologies, 
Thermofisher).
egfr CASSRI Loss of heterozygosity (LOH) analysis
About 50–100 ng of genomic DNA was amplified in a 
volume of 25 µL, 10 pmol of each primer, 0.25 mM each 
dNTP, 2.5 mM MgCl2, 3 units of AmpliTaq Gold, 1X Taq 
Gold buffer (AB, Life Technologies, Thermofisher), and 
the appropriate volume of H2O. The thermocycle PCR 
protocol as follows: 95 ℃ for 10 min, 30 cycles of 95 ℃ 
for 30 sec, 58 ℃ for 30 sec, 72 ℃ for 30 sec, and a final 
extension at 60°C for 30 min to obtain greater number 
of fragments with A-tailed ends. From 1 to 2 µL of PCR 
reaction products were added to a mix containing 0.5 µL 
GENESCAN 500 LIZ fluorescent size standard and Hi-
Di formamide (AB, Life Technologies, Thermofisher), 
denatured for 5 min at 94 ℃ and loaded onto the Genetic 
Analyzer. Products were capillary electrophoresed and 
the data processed by GeneMapper 4.0 Analysis Software 
(AB, Life Technologies, Thermofisher). The analyses were 
performed at least in duplicates of independent PCRs.
EGFR-FISH analysis
The EGFR/CEN-7 Probe Mix (Dako) detects the copy 
number of the egfr genes located on chromosome 7p11.2 
using the chromosome 7 centromere region as a reference 
(chromosome 7 copy number detection). The Texas Red-
labeled DNA probe (EGFR) binds to a 196 kb segment 
containing the egfr gene on chromosome 7p11.2. The 
fluoroscein-labelled PNA probe (CEN-7) binds to the 
centromeric region of chromosome 7. In brief, 2 µm thick 
paraffin sections were deparaffinized, dehydrated in ethanol, 
and air-dried. Sections were digested with Pepsin at 37 ℃ 
for 25 minutes. Slides were placed on a pre-programmed, 
humidified slide warmer (Hybridize; DAKO) with the 
following settings: denaturation at 82 ℃ for 5 minutes and 
hybridization at 45 ℃ for 18 hours. After hybridization, 
the slides were placed in a staining jar containing diluted 
Stringent Wash Buffer at room temperature after removing 
the Coverslips. As soon as coverslips had been removed, 
slides were transferred from the room temperature, jar was 
pre-washed to the 65 ℃ jar in the water bath. Stringent wash 
was performed for 10 minutes. Subsequently, slides were 
placed in a wash buffer and dehydrated through a graded 
series of ethanol: 2 minutes in 70% ethanol, 2 minutes 
in 85% ethanol, 2 minutes in 96% ethanol. After drying, 
each slide was covered with 10µL of Fluorescence Mounting 
Medium containing DAPI and applied a glass coverslip. 
The FISH results were assessed with an epi-fluorescence 
microscope (Zeiss, Axioscope 40) equipped with Image 
Processing analysis software (Media Cybernetics) able to 
DAPI/specific Texas Red and FITC single filters. Normal 
thymic tissue sections were included in each FISH assay as 
negative control.
Table S1 Nucleotide sequence of primers utilized to amplify two DNA regions (egfr exon 21 and egfr CA-SSR-1 locus). Fw (Forward), 
Rw (Reverse). For CA-SSR-1 locus amplification reverse primer was 5’ end fluorescence-labeled with 6-carboxy-fluorescein (6-FAM)
egfr exon 21 Fw 5’-TTCATGCGCCTTTCCATTCTTT-3’
Rv 5’-CTGGTCCCTGGTGTCAGGAAA-3’
CA-SSR-1 locus Fw 5’- GTTTGAAGAATTTGAGCCAACC- 3’
Rv 6-FAM-5’-TTCTGTCTGCACACTTGGCAC-3’
Figure S1 egfr-FISH in one case (No. 36) “monosomic” for 
chromosome 7. One green (centromere) and one red (egfr gene) 
signal cell.
egfr-FISH in one case (No.36) “monosomic” for chromosome 7.
One green (centromere) and one red (egfr gene) signal/cell
